These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 32208115)
21. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). You W; Shang B; Sun J; Liu X; Su L; Jiang S Oncol Rep; 2020 Aug; 44(2):424-437. PubMed ID: 32627031 [TBL] [Abstract][Full Text] [Related]
22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
23. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345 [TBL] [Abstract][Full Text] [Related]
24. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. Italiano A; Bellera C; D'Angelo S J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039 [TBL] [Abstract][Full Text] [Related]
25. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Fan J; Shen X; Wang Y; Zhou HL; Liu G; Li YL; Xu ZX Biomed Pharmacother; 2020 Oct; 130():110621. PubMed ID: 34321165 [TBL] [Abstract][Full Text] [Related]
26. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
27. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. Miyashita H; Mikami T; Satoi S; Cruz C; Galsky MD J Immunother; 2020; 43(9):291-298. PubMed ID: 32960847 [TBL] [Abstract][Full Text] [Related]
28. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report. Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242 [TBL] [Abstract][Full Text] [Related]
29. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Setordzi P; Chang X; Liu Z; Wu Y; Zuo D Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617 [TBL] [Abstract][Full Text] [Related]
30. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Nishijima TF; Shachar SS; Nyrop KA; Muss HB Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115 [TBL] [Abstract][Full Text] [Related]
31. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895 [TBL] [Abstract][Full Text] [Related]
32. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis. Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798 [TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596 [TBL] [Abstract][Full Text] [Related]
34. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets. Liang B; Hu X; Ding Y; Liu M J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291 [TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related]
36. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy. Fang XN; Fu LW Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881 [TBL] [Abstract][Full Text] [Related]
37. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. Hwang I; Park I; Yoon SK; Lee JL Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940 [TBL] [Abstract][Full Text] [Related]
38. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Yi M; Zheng X; Niu M; Zhu S; Ge H; Wu K Mol Cancer; 2022 Jan; 21(1):28. PubMed ID: 35062949 [TBL] [Abstract][Full Text] [Related]
39. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
40. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]